Trial Profile
Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Treosulfan (Primary)
- Indications Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Medac
- 30 Apr 2020 Status changed from active, no longer recruiting to completed.
- 17 Jan 2020 This trial is completed in Austria, UK, and Germany (Global End Date: 30 Sep 2019), according to European Clinical Trials Database.
- 20 Dec 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.